Previous Close | 29.05 |
Open | 29.54 |
Bid | 11.95 x 1000 |
Ask | 39.00 x 1100 |
Day's Range | 28.93 - 30.38 |
52 Week Range | 18.43 - 42.25 |
Volume | |
Avg. Volume | 191,750 |
Market Cap | 1.326B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.37 |
Earnings Date | May 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4,169.54 |
Subscribe to Yahoo Finance Plus to view Fair Value for IMCR
Today is shaping up negative for Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders, with the analysts delivering a...
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable or metastatic uveal melanoma Promotional launches and sales of KIMMTRAK ongoing in U.S., Germany, and France All patients in U.S. early access program successfully transitioned to commercial supply in Q1 Plan to report Phase 1 data from ImmTAC clinical candidates targeting PRAME (3Q 2022) and MAGE-A4 (
The big shareholder groups in Immunocore Holdings plc ( NASDAQ:IMCR ) have power over the company. Institutions will...